Company Update (NYSE:LLY): Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

[PR Newswire] – RIDGEFIELD, Conn and INDIANAPOLIS, Aug. 20, 2015 /PRNewswire/ — Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical . . . → Read More: Company Update (NYSE:LLY): Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – FDA asks panel to weigh benefit, risk of Lilly lung cancer drug Market Update (NYSE:LLY): U.S. FDA warns on newer class of type 2 diabetes drugs Company Update (NYSE:LLY): Lilly delays submission to market once-daily diabetes drug